How long does decreased appetite typically persist after receiving Vaxneuvance (15‑valent pneumococcal conjugate vaccine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 26, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Decreased Appetite After Vaxneuvance: Duration

Decreased appetite following Vaxneuvance (15-valent pneumococcal conjugate vaccine) typically resolves within 7 days, with most cases being mild to moderate and lasting ≤3 days. 1

Expected Timeline

  • Monitoring period: Decreased appetite is tracked as a solicited adverse reaction for 14 days post-vaccination in clinical trials, though most symptoms resolve much earlier. 1

  • Peak occurrence: The symptom occurs within the first 7 days after vaccination, consistent with other pneumococcal conjugate vaccines. 2

  • Typical duration: The majority of adverse events, including decreased appetite, last ≤3 days and are of mild-to-moderate intensity. 3

Incidence Data by Age Group

Infants (catch-up vaccination 7-11 months):

  • Decreased appetite occurred in 15.6% of Vaxneuvance recipients versus 18.8% with PCV13. 1

Toddlers (12-23 months):

  • Decreased appetite occurred in 22.6% of Vaxneuvance recipients versus 18.8% with PCV13. 1

Children (2-17 years):

  • Decreased appetite occurred in 2.3% of Vaxneuvance recipients versus 2.9% with PCV13. 1

Infants (routine 4-dose series):

  • Decreased appetite was reported in 38.7% of PCV13 recipients (comparable vaccine) across all doses. 2

Clinical Context

  • Severity: When decreased appetite does occur, it is classified as moderate (definitely acting like something is wrong) in only 0.6% of children 2-17 years, with no severe cases reported. 1

  • Comparison to other pneumococcal vaccines: The safety profile of Vaxneuvance is generally comparable to PCV13, with decreased appetite being one of the common solicited reactions across all pneumococcal conjugate vaccines. 1, 3

  • No discontinuations: No participants discontinued the vaccine due to adverse events, including decreased appetite, in clinical trials. 3

Practical Management

  • Reassure parents/patients that decreased appetite is self-limited and typically resolves within 3-7 days without intervention. 1, 3

  • If decreased appetite persists beyond 14 days, consider alternative etiologies unrelated to vaccination. 1

  • The symptom does not require dose adjustment or discontinuation of the vaccination series. 3

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What are the management and monitoring recommendations for a 6-month-old infant who received the COVID-19 (Coronavirus Disease 2019) vaccine dose intended for 5-11 year olds?
Can I receive Pneumococcal Conjugate Vaccine (PCV) 13 two months after completing Herceptin (Trastuzumab) therapy?
Can a patient with a pneumococcal vaccine allergy receive Pulmicort (budesonide)?
What is the management for a local reaction to the pneumococcal (pneumonia) vaccine?
What are the steps to manage a reaction to the pneumococcal (pneumo) vaccine?
What is the best first‑line oral iron supplement and dosing regimen for a 5‑year‑old girl with iron‑deficiency anemia?
What is the appropriate management if the second dose of the post‑exposure rabies vaccine (intramuscular schedule days 0, 3, 7, 14, 28) is missed?
What are the differential diagnoses for an 18‑year‑old woman with a 10‑day history of fever, dry cough, loss of appetite and weight loss, a normal total leukocyte count (~8000/µL), a negative Cartridge Based Nucleic Acid Amplification Test (CBNAAT) on sputum, and a chest X‑ray showing dense consolidation in the right upper lobe?
For a patient with resistant hypertension on three antihypertensive agents including a thiazide diuretic, which α‑1 blocker—doxazosin or prazosin—is the more appropriate choice?
In an 85‑year‑old man with chronic brown‑black velvety plaques on the face, neck and dorsal hands, central obesity, pre‑diabetic HbA1c, benign prostatic hyperplasia treated with finasteride, and donepezil for cognition, what is the most likely diagnosis and recommended management?
How should a PCOS flare be treated, including lifestyle modifications, combined oral contraceptives, anti‑androgen therapy, metformin, and ovulation induction options?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question